Oramed Pharmaceuticals Inc. (ORMP)
$
2.06
-0.02 (-0.97%)
Key metrics
Financial statements
Free cash flow per share
-0.1591
Market cap
85 Million
Price to sales ratio
0
Debt to equity
0.0027
Current ratio
27.0764
Income quality
0.7301
Average inventory
0
ROE
-0.0532
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Oramed Pharmaceuticals Inc. is dedicated to the research and development of innovative pharmaceutical solutions aimed at treating diabetes, particularly through the use of orally ingestible capsules or pills for delivering polypeptides. The company’s flagship product, ORMD-0801, is an insulin capsule that has successfully completed phase II clinical trials for diabetes management. Additionally, Oramed is advancing its pipeline with ORMD-0901, an oral glucagon-like peptide-1 capsule that has finished phase I clinical trials targeting type 2 diabetes. The company is also working on an oral leptin capsule intended for weight loss treatment. The operating expenses amount to $17,109,000.00 encompassing various operational costs incurred during these developments. The gross profit ratio is 1.00 reflecting the efficiency of the company's production and sales operations. Furthermore, the net income ratio is 4.12 providing insights into the profitability margin of the business. The company reported depreciation and amortization expenses of $196,000.00 indicating the wear and tear of its assets. Ultimately, Oramed Pharmaceuticals Inc. recorded a net income of $5,525,000.00 reflecting its profitability within the competitive market. In the financial landscape, the stock of Oramed Pharmaceuticals is accessible at $2.13 making it a suitable choice for budget-conscious investors looking for entry points in the market. However, the stock experiences a low average trading volume of 74,587.00 which suggests lower market activity and liquidity. With a market capitalization of $84,140,906.00 the company is classified as a small-cap player, which may appeal to certain investors seeking growth opportunities. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and positioning itself as a noteworthy contender in diabetes treatment. Additionally, Oramed Pharmaceuticals belongs to the Healthcare sector, where it drives innovation and growth amidst evolving healthcare challenges and opportunities.
Is Oramed Pharmaceuticals Inc. (ORMP) a good investment?
Investing in Oramed Pharmaceuticals Inc. (ORMP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Oramed Pharmaceuticals Inc. (ORMP)'s stock forecast?
Analysts predict Oramed Pharmaceuticals Inc. stock to fluctuate between $1.82 (low) and $3.09 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Oramed Pharmaceuticals Inc.'s market capitalization?
As of 2025-08-20, Oramed Pharmaceuticals Inc.'s market cap is $84,140,906, based on 40,845,100 outstanding shares.
How does Oramed Pharmaceuticals Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Oramed Pharmaceuticals Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Oramed Pharmaceuticals Inc. (ORMP) stock?
To buy Oramed Pharmaceuticals Inc. (ORMP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ORMP. Place an order (Market, Limit, etc.).
What is the best time to invest in Oramed Pharmaceuticals Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Oramed Pharmaceuticals Inc. stock ever split?
Oramed Pharmaceuticals Inc.'s last stock split was 1:12 on 2013-01-23.
How did Oramed Pharmaceuticals Inc. perform in the last earnings report?
Revenue: $1,340,000 | EPS: $0.14 | Growth: -114.43%.
Where can I find Oramed Pharmaceuticals Inc.'s investor relations reports?
Visit https://www.oramed.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Oramed Pharmaceuticals Inc.?
You can explore historical data from here
What is the all-time high and low for Oramed Pharmaceuticals Inc. stock?
All-time high: $31.54 (2021-11-03) | All-time low: $1.67 (2023-11-02).
What are the key trends affecting Oramed Pharmaceuticals Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
4 months ago
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the “offering”) whereby an affiliate of Oramed Pharmaceuticals Inc. (“Oramed”) (Nasdaq: ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share.
prnewswire.com
4 months ago
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK , April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®.
prnewswire.com
6 months ago
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.
prnewswire.com
6 months ago
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq. OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology.
investorplace.com
a year ago
When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million.
prnewswire.com
2 years ago
Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing NEW YORK , Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you an update regarding Oramed.
prnewswire.com
2 years ago
18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento Therapeutics NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed.
prnewswire.com
2 years ago
JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million, Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to advance registration of oral insulin in the United States and other countries NEW YORK , Aug. 2, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. ("HTIT") to establish a joint venture ("JV") based on Oramed's oral drug delivery technology.
pennystocks.com
2 years ago
Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today?
fool.com
3 years ago
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.
See all news
